Progyny, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 500.62M | 786.91M | 1.09B | 1.17B | 1.29B | 10.4% | |
| Cost of Revenue | (388.49M) | (619.59M) | (849.80M) | (913.86M) | (984.18M) | 7.7% | |
Gross Profit | 112.14M | 167.32M | 238.80M | 253.36M | 304.48M | 20.2% | |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | |
| Selling, General & Administrative | (79.80M) | (143.98M) | (176.62M) | (185.91M) | (219.21M) | 17.9% | |
| General & Administrative | (59.62M) | (98.33M) | (117.13M) | (121.96M) | (147.09M) | 20.6% | |
| Selling & Marketing | (20.18M) | (45.66M) | (59.49M) | (63.95M) | (72.11M) | 12.8% | |
| Depreciation & Amortization | (1.30M) | (1.60M) | (2.28M) | (3.17M) | (4.95M) | 55.8% | |
Operating Income (EBIT) | 32.34M | 23.34M | 62.18M | 67.45M | 85.28M | 26.4% | |
| Non-Operating Items | |||||||
| Interest Income | 461.00K | 814.00K | 8.51M | 15.75M | 10.15M | -35.5% | |
| Interest Expense | — | — | — | — | — | — | |
| Other Income/Expenses (Net) | 95.00K | 1.10M | 8.51M | 15.75M | 10.15M | -35.5% | |
Income Before Tax | 32.44M | 24.44M | 70.69M | 83.20M | 95.43M | 14.7% | |
| Income Tax Expense | (33.33M) | (5.92M) | (8.65M) | (28.87M) | (36.91M) | 27.9% | |
Net Income | 65.77M | 30.36M | 62.04M | 54.34M | 58.52M | 7.7% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $1 | $0 | $1 | $1 | $1 | 15.3% | |
| Weighted Avg Shares Outstanding | 89.11M | 92.20M | 95.02M | 91.48M | 85.23M | -6.8% | |
| Weighted Avg Shares Outstanding (Diluted) | 100.36M | 99.96M | 100.67M | 95.45M | 89.46M | -6.3% | |
EBITDA | 33.74M | 26.04M | 72.97M | 86.38M | 100.38M | 16.2% |
Explore PGNY
PGNY in the Healthcare
Mid Cap